ArticleNature communications2019
The molecular origin and taxonomy of mucinous ovarian carcinoma.
Open access · goldAbstract readMulticenter Study
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed, 2 pooled it
17.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Guideline
- Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.Genome medicine · 2021Pooled it
- Profiling tumor immune microenvironment of epithelial ovarian carcinoma.Oncoimmunology · 2026Article
- DNA methylation profiling enables subclassification of mucinous ovarian carcinoma and distinguishes it from extraovarian mucinous metastases.Cell reports. Medicine · 2026Article
- Long-read, whole-genome sequencing and chemotherapy response of two patient-derived organoids from a TP53- and KRAS-mutant ovarian carcinoma.bioRxiv : the preprint server for biology · 2026Article
- Liquid Biopsy-Based Metabolomics in Epithelial Ovarian Cancer: Challenges, Methodological Advances and Translational Considerations.Diagnostics (Basel, Switzerland) · 2026Review
- Oncofertility outcomes after fertility-sparing surgery for borderline ovarian tumors: results of a large retrospective study.Journal of ovarian research · 2026Article
- Ovarian cancer.Nature reviews. Disease primers · 2026Review
- Integrative genomic analysis identifies clinically relevant prognostic markers for colorectal cancer patients with liver metastasis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Identifying and capitalizing on unique molecular alterations of mucinous ovarian carcinoma for the development of novel therapeutic strategies.Gynecologic oncology reports · 2026Article
- A 5-marker immunohistochemical panel of CK17, MEP1A, PAX8, SMAD4, and CDX2 to distinguish ovarian mucinous carcinoma from metastatic pancreatic ductal adenocarcinoma.Histopathology · 2026Article
- Synchronous primary breast invasive carcinoma and breast metastasis from high-grade serous ovarian carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- SWI/SNF protein expression in anaplastic carcinomatous mural nodules of ovarian mucinous tumors.Virchows Archiv : an international journal of pathology · 2025Article
- Primary mucinous cystadenocarcinoma of the breast commonly harbours TP53 mutations and PI3K/AKT pathway alterations.Virchows Archiv : an international journal of pathology · 2025Article
- Amino acid-dependent TSC2 dephosphorylation by lysosome-PP2A regulates mTORC1 signaling transduction.Life science alliance · 2025Article
- Genomic Landscapes of Endometrioid and Mucinous Ovarian Cancers and Morphologically Similar Tumor Types.Cancer research communications · 2025Article
- Diagnostic and prognostic biomarkers associated with histotype in advanced epithelial ovarian cancer.Scientific reports · 2025Article
- Mucinous cystic neoplasms of the pancreas and liver share a similar DNA methylation profile with mucinous ovarian tumors.The Journal of pathology · 2025Article
- FOXA1 expression and its association with mucin expression and KRAS mutation in ovarian mucinous tumors: implications for tumor progression and differentiation.Virchows Archiv : an international journal of pathology · 2025Article
- Mucinous Ovarian Carcinoma: Integrating Molecular Stratification into Surgical and Therapeutic Management.Biomedicines · 2025Review
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors at 20 institutions in 4 countries.
Dane CheasleyPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-1170-4690
Matthew J WakefieldWalter and Eliza Hall Institute, Parkville, Australia.ORCID http://orcid.org/0000-0001-6624-4698
Georgina L RylandPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-4990-0961
Prue E AllanPeter MacCallum Cancer Centre, Melbourne, Australia.
Kathryn AlsopPeter MacCallum Cancer Centre, Melbourne, Australia.
Kaushalya C AmarasinghePeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0001-6024-657X
Sumitra AnandaPeter MacCallum Cancer Centre, Melbourne, Australia.
Michael S AnglesioUniversity of British Columbia, Vancouver, Canada.ORCID http://orcid.org/0000-0003-1639-5003
George Au-YeungPeter MacCallum Cancer Centre, Melbourne, Australia.
Maret BöhmKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Australia.
David D L BowtellPeter MacCallum Cancer Centre, Melbourne, Australia.
Alison BrandWestmead Hospital, University of Sydney, Sydney, Australia.
Georgia Chenevix-TrenchQueensland Institute of Medical Research, Brisbane, Australia.
Michael ChristieThe University of Melbourne, Melbourne, Australia.
Yoke-Eng ChiewWestmead Hospital, University of Sydney, Sydney, Australia.
Michael ChurchmanNicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.
Anna DeFazioWestmead Hospital, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-0057-4744
Renee DemeoPeter MacCallum Cancer Centre, Melbourne, Australia.
Rhiannon DudleyHudson Institute of Medical Research, Clayton, Australia.
Nicole FairweatherHudson Institute of Medical Research, Clayton, Australia.
Clare G FedelePeter MacCallum Cancer Centre, Melbourne, Australia.
Sian FeredayPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-8559-8579
Stephen B FoxPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-7648-8896
C Blake GilksUniversity of British Columbia, Vancouver, Canada.
Charlie GourleyNicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK.ORCID http://orcid.org/0000-0002-2377-7221
Neville F HackerThe University of New South Wales, Sydney, Australia.
Alison M HadleyRoyal Brisbane and Womens Hospital, Brisbane, Australia.
Joy HendleyPeter MacCallum Cancer Centre, Melbourne, Australia.
Gwo-Yaw HoWalter and Eliza Hall Institute, Parkville, Australia.ORCID http://orcid.org/0000-0003-1195-2296
Siobhan HughesPeter MacCallum Cancer Centre, Melbourne, Australia.
David G HunstmanUniversity of British Columbia, Vancouver, Canada.
Sally M HunterPeter MacCallum Cancer Centre, Melbourne, Australia.
Tom W JoblingMonash Medical Centre, Clayton, Australia.
Kimberly R KalliMayo Clinic, Rochester, MN, USA.
Scott H KaufmannMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4900-7145
Catherine J KennedyWestmead Hospital, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0002-4465-5784
Martin KöbelThe University of Calgary, Calgary, Canada.ORCID http://orcid.org/0000-0002-6615-2037
Cecile Le PageCRCHUM, Montreal, Canada.ORCID http://orcid.org/0000-0002-8020-1544
Jason LiPeter MacCallum Cancer Centre, Melbourne, Australia.
Richard LupatPeter MacCallum Cancer Centre, Melbourne, Australia.
Orla M McNallyThe University of Melbourne, Melbourne, Australia.
Jessica N McAlpineUniversity of British Columbia, Vancouver, Canada.ORCID http://orcid.org/0000-0001-6003-485X
Anne-Marie Mes-MassonCRCHUM, Montreal, Canada.
Linda MileshkinPeter MacCallum Cancer Centre, Melbourne, Australia.
Diane M ProvencherCRCHUM, Montreal, Canada.
Jan PymanRoyal Womens Hospital, Parkville, Australia.
Kurosh RahimiCRCHUM, Montreal, Canada.
Simone M RowleyPeter MacCallum Cancer Centre, Melbourne, Australia.
Carolina SalazarPeter MacCallum Cancer Centre, Melbourne, Australia.
Goli SamimiKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Australia.
Hugo SaundersPeter MacCallum Cancer Centre, Melbourne, Australia.
Timothy SemplePeter MacCallum Cancer Centre, Melbourne, Australia.
Ragwha SharmaWestmead Hospital, University of Sydney, Sydney, Australia.
Alice J SharpeMonash University, Clayton, Australia.
Andrew N StephensHudson Institute of Medical Research, Clayton, Australia.ORCID http://orcid.org/0000-0003-2420-8458
Niko ThioPeter MacCallum Cancer Centre, Melbourne, Australia.
Michelle C TorresPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-1275-4446
Nadia TraficantePeter MacCallum Cancer Centre, Melbourne, Australia.
Zhongyue XingPeter MacCallum Cancer Centre, Melbourne, Australia.
Magnus ZethovenPeter MacCallum Cancer Centre, Melbourne, Australia.
Yoland C AntillCabrini Health, Malvern, Australia.
Clare L ScottPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-3689-5956
Ian G CampbellPeter MacCallum Cancer Centre, Melbourne, Australia.ORCID http://orcid.org/0000-0002-7773-4155
Kylie L GorringePeter MacCallum Cancer Centre, Melbourne, Australia. kylie.gorringe@petermac.org.ORCID http://orcid.org/0000-0001-5681-2022
Peter MacCallum Cancer Centre · AUThe University of Melbourne · AUThe University of Sydney · AUUniversity of British Columbia · CAHudson Institute of Medical Research · AUCentre Hospitalier de l’Université de Montréal · CAEdinburgh Cancer Research · GBGarvan Institute of Medical Research · AUMayo Clinic in Arizona · USThe Royal Melbourne Hospital · AUFrankston Hospital · AUMonash Medical Centre · AUMonash University · AUQIMR Berghofer Medical Research Institute · AURoyal Brisbane and Women's Hospital · AURoyal Children's Hospital · AURoyal Women's Hospital · AUUniversité de Montréal · CAUniversity of Calgary · CAUNSW Sydney · AU
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MGenetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7MNCI NIH HHS P30 CA015083NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA122443
Abstract
Mucinous ovarian carcinoma (MOC) is a unique subtype of ovarian cancer with an uncertain etiology, including whether it genuinely arises at the ovary or is metastatic disease from other organs. In addition, the molecular drivers of invasive progression, high-grade and metastatic disease are poorly defined. We perform genetic analysis of MOC across all histological grades, including benign and borderline mucinous ovarian tumors, and compare these to tumors from other potential extra-ovarian sites of origin. Here we show that MOC is distinct from tumors from other sites and supports a progressive model of evolution from borderline precursors to high-grade invasive MOC. Key drivers of progression identified are TP53 mutation and copy number aberrations, including a notable amplicon on 9p13. High copy number aberration burden is associated with worse prognosis in MOC. Our data conclusively demonstrate that MOC arise from benign and borderline precursors at the ovary and are not extra-ovarian metastases.
Indexed as
Adenocarcinoma, MucinousCarcinoma, Ovarian EpithelialCohort StudiesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMutationOvarian NeoplasmsSequence Analysis, DNASurvival Analysis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.